NCT03109353View on ClinicalTrials.gov

Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Cutaneous T-Cell Lymphoma, UnspecifiedChronic Graft Versus Host Disease in Skin
Interventions
DRUG

ECP with 5-aminolevulinic acid

extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles

Trial Locations (1)

Unknown

St Olavs Hospital, Trondheim

All Listed Sponsors
collaborator

Norwegian University of Science and Technology

OTHER

collaborator

Oslo University Hospital

OTHER

lead

St. Olavs Hospital

OTHER

NCT03109353 - Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease | Biotech Hunter | Biotech Hunter